A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
Status:
Completed
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
This is an open label, multi-center, Phase 1/2 dose escalation study of BBI608 administered
in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with
and without bevacizumab, or regorafenib, or irinotecan.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Boston Biomedical, Inc Sumitomo Dainippon Pharma Oncology, Inc